A large analysis of nine clinical trials involving more than 3,200 people found that long-acting injectable antiretroviral therapy (LAI) works just as well as standard daily oral pills at keeping HIV suppressed. The study, which combined data from head-to-head trials, showed that the two approaches were equivalent in achieving viral suppression below 50 copies per milliliter.
However, when researchers compared trial results to real-world outcomes in Southern China, the picture became more complicated. In one trial, people on injectable therapy did better than those on oral therapy in the local population. In another trial, the injectable group did worse. This suggests that global trial results may not always apply directly to specific regions or patient groups.
The analysis included 2,590 people with unsuppressed HIV and 3,123 with suppressed HIV from Southern China, plus participants from global trials. No safety data were reported in this analysis.
The main takeaway is that long-acting injectable HIV treatment is a proven option, but its effectiveness can depend on local factors like patient demographics and the type of oral therapy used for comparison. Patients should discuss with their doctor whether injectable therapy is right for them.
